Safety of Lanreotide 120 mg ATG in Combination With Metformin in Patients With Progressive Advanced Well-differentiated Gastro-intestinal (GI) or Lung Carcinoids: A Pilot, One-arm, Open-label, Prospective Study: the MetNET-2 Trial
Latest Information Update: 05 Jun 2023
At a glance
- Drugs Lanreotide (Primary) ; Metformin
- Indications Gastrointestinal cancer; Lung cancer
- Focus Adverse reactions
- Acronyms MetNET-2
- 04 Jun 2021 Planned End Date changed from 1 Apr 2022 to 1 Dec 2021.
- 04 Jun 2021 Planned primary completion date changed from 1 Apr 2022 to 1 Dec 2021.
- 04 Jun 2021 Status changed from recruiting to active, no longer recruiting.